BioSenic presents new Phase III data on JTA-004 in osteoarthritis pain

Belgian cell therapy biotech BioSenic (Euronext: BIOS) will, for the first time, share post hoc data on its late-clinical asset JTA-004 at the Osteoarthritis Research Society International (OARSI) World Congress 2024, sending the firm’s shares 4% higher in early trading.

The post hoc analysis of a Phase III study found that a single injection of JTA-004 was safe and efficacious for patients with a newly characterized severe inflammatory subtype of knee osteoarthritis (OA), said BioSenic, which changed its name from Bone Therapeutics in October 2022.

JTA-004 is an innovative intra-articular viscosupplement treatment for knee OA, composed of hyaluronic acid, plasmatic proteins, and clonidine. The post-hoc analysis addresses different subpopulations of OA patients in the data of a Phase III trial (KOA-2) completed in 2019. The trial was intended to demonstrate that treatment with JTA-004 leads to a reduction in knee pain intensity compared to saline solution or Synvisc-One(R), three months after injection, in subjects suffering from symptomatic knee OA.